Home Nucleus Biotechnology U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032

U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The U.S. Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 943.19 USD Billion by 2032 and is projected to grow at a CAGR of 15.50% from 2025 to 2032.

Revenue, 2024 (USD Billion)
444.03
Forecast, 2032 (USD Billion)
943.19
CAGR, 2024 - 2032
15.50%
Report Coverage
U.S.

U.S. Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

U.S. Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 444.03 USD Billion
  • Projected Market Size (2032): 943.19 USD Billion
  • CAGR (2025-2032): 15.50%

Key Findings of U.S. Pharmacogenetic Testing in Psychiatry depression Market

  • The U.S. Pharmacogenetic Testing in Psychiatry depression Market was valued at 444.03 USD Billion in 2024.
  • The U.S. Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 15.50% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 344.82 USD Billion
  • The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 20.68% during the forecast period from 2024 to 2032.

U.S. Pharmacogenetic Testing in Psychiatry depression Market Scope

U.S. Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • HLA-B
  • Others
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs

U.S. Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Billion
Market Value in 2024 444.03 USD Billion
Market Value in 2032 943.19 USD Billion
CAGR (2025-2032) 15.50%
Historic Data 2016-2023
Market Segments Covered Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type

Regional Insights:

  • Leading Market (2024-2032): U.S., leading in terms of revenue 444.03 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 444.03 USD Billion in 2024.

Segments and Scope

  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
    • CYP2C19 is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 100.60 USD Billion in the year 2024.
    • CYP2C19 is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 20.68 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
    • Whole Genome Sequencing is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 271.34 USD Billion in the year 2024.
    • Whole Genome Sequencing is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.08 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
    • Retail Pharmacies is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 208.60 USD Billion in the year 2024.
    • Retail Pharmacies is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.46 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
    • Pharmaceutical & Biotechnology Companies is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 189.66 USD Billion in the year 2024.
    • Pharmaceutical & Biotechnology Companies is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.68 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
    • Drug Development is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 246.07 USD Billion in the year 2024.
    • Drug Development is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 16.20 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
    • Saliva is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 344.82 USD Billion in the year 2024.
    • Saliva is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 15.80 % in forecast period 2025-2032.
  • U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
    • Prescription Drugs is the largest segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 220.09 USD Billion in the year 2024.
    • Recreational Drugs is the Fastest growing segment in U.S. Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 15.96 % in forecast period 2025-2032.

U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

 
Company Name Company Share Analysis
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

U.S. Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Industry Related Reports

South America Cell And Gene Therapy Thawing Equipment Market
Middle East & Africa Cell And Gene Therapy Thawing Equipment Market
North America Cell And Gene Therapy Thawing Equipment Market
Europe Cell And Gene Therapy Thawing Equipment Market
Asia-Pacific Cell And Gene Therapy Thawing Equipment Market
Argentina Cell And Gene Therapy Thawing Equipment Market
Australia Cell And Gene Therapy Thawing Equipment Market
Belgium Cell And Gene Therapy Thawing Equipment Market
Brazil Cell And Gene Therapy Thawing Equipment Market
Canada Cell And Gene Therapy Thawing Equipment Market
Frequently Asked Questions
The U.S. Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type.
U.S. Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 444.03(Revenue in USD Billion) in 2020.
U.S. Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 15.50% during the forecast period of 2024 to 2032.
The Saliva segment is expected to dominate the U.S. Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 344.82 USD Billion in 2024

U.S. Pharmacogenetic Testing in Psychiatry depression Market Scope

U.S. Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • HLA-B
  • Others
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
Frequently Asked Questions
The U.S. Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type.
U.S. Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 444.03(Revenue in USD Billion) in 2020.
U.S. Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 15.50% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 943.19 (USD Billion).

U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

U.S. Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The U.S. Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Genes,Type,Distribution Channel,End User,Application,Sample,Drug Type.
U.S. Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 444.03(Revenue in USD Billion) in 2020.
U.S. Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 15.50% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 943.19 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES